Tallinn veterinary-medicines factory can make Estonia’s annual need in four hours

The establishment of a €50 million veterinary-medicines factory in Tallinn creates domestic production capacity for a nationally important supply. Pharmapark Production OÜ says the plant can complete Estonia’s annual need in four hours, although the source does not identify a public contract or tender linked to the investment.

A factory built around domestic supply

Pharmapark Production OÜ has established a veterinary-medicines factory in Tallinn at a reported cost of €50 million. Chief executive Veiko Saluste said the facility can produce Estonia’s annual need in four hours. That capacity claim places the project beyond the scale of a conventional local manufacturing site: it is presented as infrastructure capable of meeting the country’s full requirement for a defined category of medicines. The source does not say that the state commissioned the factory, awarded a contract to it or guaranteed purchases. The procurement significance is therefore the creation of domestic supply capacity, rather than a disclosed public tender outcome.

What the procurement mechanism is — and is not

A public buyer normally meets a national requirement by specifying the products and conditions it needs, then selecting suppliers through a competitive procedure or another permitted purchasing route. A manufacturer may qualify to bid, supply through an intermediary or support resilience without receiving a dedicated construction award. In this case, the available information describes a private production investment and its output potential, not the terms of a procurement procedure. That distinction matters for businesses assessing the opportunity: factory capacity can make a supplier more credible for future purchasing, but capacity alone does not establish a contract, a preferred-supplier position or a public-sector obligation to buy.

Saluste’s industrial build-out

Saluste said he had established four factories in Estonia and one in Lithuania, describing the process as having taken him through “fire, water and copper pipes”. He said the company had now reached the point of actual production. The Tallinn plant is therefore presented as the latest stage in an industrial operating model, rather than only a construction project. The company’s intended route to profitability, the production volumes beyond Estonia’s requirement and the additional customers it plans to serve are identified as matters for the company’s business plan. The source does not provide the plant’s staffing, sales forecasts or confirmed customer list.

European rules could reshape the market

The reported business case also depends on changes in the wider veterinary-medicines market. Saluste’s assessment is that new European Union requirements could reshape production across Europe. The source does not set out those requirements or quantify their effect, so the claim remains an executive assessment rather than an established market result. For public buyers, the transferable issue is how regulatory change can alter the supplier base: manufacturing location, compliance capability and available capacity may become relevant when requirements are designed. Any future procurement would still need to define the need and assess competing offers under the applicable rules.

Reported from aripaev.ee, 2026-11-02. The Tender Wire is published by Otnox.